Update on Phase II Trial by Immunocellular Therapeutics ICT 107 for Newly Diagnosed Glioblastoma

IMG_6904

Charles S. Cobbs, MD

The Gregory Foltz, MD Endowed Director Ben & Catherine Ivy Center for Advanced Brain Tumor Treatment Swedish Neuroscience Specialists

 

A recent presentation at the American Society for Clinical Oncology  (ASCO) meeting in Chicago this month shows some suggestion of efficacy of the ImmunoCellular Therapeutics immunotherapy vaccine ICT-107.   http://www.marketwatch.com/story/immunocellular-therapeutics-presents-updated-ict-107-phase-ii-data-in-patients-with-newly-diagnosed-glioblastoma-at-the-2014-asco-annual-meeting-2014-06-01  The vaccine was developed after the company identified 6 proteins that seem to be associated with glioblastoma. These 6 proteins are introduced into a patient’s own dendritic cells, which are cells that are isolated from a leukapheresis blood draw from the glioblastoma patients after surgery. Dendritic cells are capable of telling the other immune cells to attack specific proteins molecules which leads to an immune response. The strategy of this ICT-107 vaccine is to have a patient’s own dendritic cells activate an immune response to these 6 tumor associated proteins leading to tumor cell death by the patient’s own immune system. The potential of immunotherapy and cancer has been increasingly appreciated since the strategy has the capacity to eliminate tumor cells without any systemic side effects other than a normal immune response. The data presented at the ASCO meeting by Dr. Patrick Wen from the Dana-Farber Cancer Institute at Harvard Medical School indicated that, compared to patients who received a control, the patients receiving the ICT 107 had improved survival. Specifically in patients with unmethylated MGMT promoter, the control patients had a median overall survival of 11.8 months whereas the ICT 107 patient’s had a median overall survival of 15.8 months. More impressive was the data relating to overall survival and progression free survival for GBM patients with methylated MGMT. The control patients had a progression free survival of 8.5 months whereas the ICT 107 patient’s had a median progression free survival of 24 months. Overall these data are promising and suggest that there is, at this point, evidence suggesting that this immunotherapy strategy may have benefit for GBM patients and that further phase 3 trials are warranted. To be a candidate for this trial however, the patient has to have a specific immune antigen type called HLA-A2. This immune status is fairly common in the population. It is hoped that this type of therapeutic option will be something that can help patients who have MGMT unmethylated tumors which essentially did not respond to temozolomide therapy. For further information, patients should contact ImmunoCellular Therapeutics, and / or Dr. John Yu at Cedars Sinai Hospital in Los Angeles.                   Disclaimer: This is a personal blog. Any views or opinions represented in this blog are personal and belong solely to the blog author and do not represent those of people, institutions or organizations that the owner may or may not be associated with in professional or personal capacity, unless explicitly stated.  All content provided on this blog is for informational purposes only. The owner of this blog makes no representations as to the accuracy or completeness of any information on this site or found by following any link on this site. The owner will not be liable for any errors or omissions in this information nor for the availability of this information. The owner will not be liable for any losses, injuries, or damages from the display or use of this information. These terms and conditions of use are subject to change at anytime and without notice. All content provided on this blog is for informational purposes only. The owner of this blog makes no representations as to the accuracy or completeness of any information on this site or found by following any link on this site. The owner will not be liable for any errors or omissions in this information nor for the availability of this information. The owner will not be liable for any losses, injuries, or damages from the display or use of this information.

Leave a Reply